Tadalafil Tablet
Product Images NDC 68071-3800

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3800). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3800 3)

Tadalafil 2.5 mg tablets prescription drug label from NuCare Pharmaceuticals, Inc. The label indicates a 30-count package with a product number R1942025. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. in China, distributed by NuCare Pharmaceuticals. Includes storage instructions and barcode identifiers.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, the active ingredient in TADALAFIL tablets. The diagram shows the molecular arrangement of atoms and bonds characteristic of tadalafil.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs comparing blood pressure changes over time in hours after tadalafil administration versus placebo. The graphs show differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure measurements, with error bars indicating variability at multiple time points up to 96 hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing the effects of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes, both measured in mmHg over time in hours.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

Line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil or placebo combined with doxazosin. Four groups are shown: 20 mg tadalafil at 08:00 with 8 mg doxazosin; placebo at 08:00 with 8 mg doxazosin; 20 mg tadalafil at 20:00 with 8 mg doxazosin; and placebo at 20:00 with 8 mg doxazosin. The y-axis represents systolic BP changes, and the x-axis shows time after administration in hours.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (μg/L) over time (hours). The graph compares single 20-mg and 5-mg tadalafil doses and once-daily 5-mg tadalafil after 5 days of administration, showing concentration trends and variability via error bars at multiple time points up to 120 hours.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. It compares Tadalafil tablets 5 mg and placebo, with Tadalafil showing a greater decrease in score over time. The X-axis represents duration of treatment in weeks, and the Y-axis shows change from baseline in IPSS total score.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

Line graph showing change from baseline in IPSS total score over a 12-week treatment duration, comparing Tadalafil tablets 5 mg to placebo. Tadalafil shows a greater decrease in score over time, with statistical significance indicated at week 4 (p<0.01).*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph comparing the least-squares mean change from baseline over 26 weeks of therapy between two groups: Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the mean change from baseline ranging approximately from 0 to -7. Data points with statistical annotations (p values) are shown for each group at weeks 4, 12, and 26.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration, comparing tadalafil tablets 5 mg and placebo. The y-axis shows the change in score, and the x-axis represents weeks of treatment, with tadalafil showing a greater decrease in score over time compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.